Organisation paid for research Program year 2025 Source: CMS Open Payments

D&H National Research Centers

Neither a doctor nor a teaching hospital

Research payments

$2,685,686

30 payments

Through program year 2025, D&H National Research Centers is reported as receiving $2,685,686 in research payments, across 30 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $34,402 1
2024 Research $2,606,742 8
2023 Research $33,592 20
2021 Research $10,950 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. Amgen Inc. $2,600,332 1 payment
  2. Eli Lilly and Company $34,402 1 payment
  3. Moderna TX, Inc. $17,660 12 payments
  4. Exeltis, USA Inc. $14,511 4 payments
  5. GW Research Limited $10,950 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $4,500 4 payments
  7. AbbVie, Inc. $3,331 7 payments
Studies the money was for Research payments · program years 2021–2025
  1. P4 Uncontrolled Gout FORWARD II $2,600,332 1 payment
  2. A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 MG and 4.5 MG in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus $34,402 1 payment
  3. LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $14,511 4 payments
  4. Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants $13,500 7 payments
  5. Gwep19022 $10,950 1 payment
  6. A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. $4,160 5 payments
  7. Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD $2,710 2 payments
  8. A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease $2,250 2 payments
  9. A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (Ee) and Maintenance of Healed Ee in Pediatric Subjects Aged 1 to 11 Years With Ee $2,250 2 payments
  10. Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $301 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record